Can biosimilars help achieve the goals of US health care reform?

Ralph Boccia, Ira Jacobs, Robert Popovian, Gilberto de Lima Lopes

Research output: Contribution to journalReview article

Abstract

The US Patient Protection and Affordable Care Act (ACA) aims to expand health care coverage, contain costs, and improve health care quality. Accessibility and affordability of innovative biopharmaceuticals are important to the success of the ACA. As it is substantially more difficult to manufacture them compared with small-molecule drugs, many of which have generic alternatives, biologics may increase drug costs. However, biologics offer demonstrated improvements in patient care that can reduce expensive interventions, thus lowering net health care costs. Biosimilars, which are highly similar to their reference biologics, cost less than the originators, potentially increasing access through reduced prescription drug costs while providing equivalent therapeutic results. This review evaluates 1) the progress made toward enacting health care reform since the passage of the ACA and 2) the role of biosimilars, including the potential impact of expanded biosimilar use on access, health care costs, patient management, and outcomes. Barriers to biosimilar adoption in the USA are noted, including low awareness and financial disincentives relating to reimbursement. The evaluated evidence suggests that the ACA has partly achieved some of its aims; however, the opportunity remains to transform health care to fully achieve reform. Although the future is uncertain, increased use of biosimilars in the US health care system could help achieve expanded access, control costs, and improve the quality of care.

LanguageEnglish (US)
Pages197-205
Number of pages9
JournalCancer Management and Research
Volume9
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

Biosimilar Pharmaceuticals
Health Care Reform
Patient Protection and Affordable Care Act
Biological Products
Health Care Costs
Drug Costs
Quality of Health Care
Delivery of Health Care
Prescription Drugs
Cost Control
Motivation
Patient Care
Costs and Cost Analysis

Keywords

  • Access
  • Affordable Care Act
  • Biologics
  • Health policy
  • Patient care

ASJC Scopus subject areas

  • Oncology

Cite this

Can biosimilars help achieve the goals of US health care reform? / Boccia, Ralph; Jacobs, Ira; Popovian, Robert; de Lima Lopes, Gilberto.

In: Cancer Management and Research, Vol. 9, 01.06.2017, p. 197-205.

Research output: Contribution to journalReview article

Boccia, Ralph ; Jacobs, Ira ; Popovian, Robert ; de Lima Lopes, Gilberto. / Can biosimilars help achieve the goals of US health care reform?. In: Cancer Management and Research. 2017 ; Vol. 9. pp. 197-205.
@article{da20dbcb0e974a59a6f6d8fac0b99228,
title = "Can biosimilars help achieve the goals of US health care reform?",
abstract = "The US Patient Protection and Affordable Care Act (ACA) aims to expand health care coverage, contain costs, and improve health care quality. Accessibility and affordability of innovative biopharmaceuticals are important to the success of the ACA. As it is substantially more difficult to manufacture them compared with small-molecule drugs, many of which have generic alternatives, biologics may increase drug costs. However, biologics offer demonstrated improvements in patient care that can reduce expensive interventions, thus lowering net health care costs. Biosimilars, which are highly similar to their reference biologics, cost less than the originators, potentially increasing access through reduced prescription drug costs while providing equivalent therapeutic results. This review evaluates 1) the progress made toward enacting health care reform since the passage of the ACA and 2) the role of biosimilars, including the potential impact of expanded biosimilar use on access, health care costs, patient management, and outcomes. Barriers to biosimilar adoption in the USA are noted, including low awareness and financial disincentives relating to reimbursement. The evaluated evidence suggests that the ACA has partly achieved some of its aims; however, the opportunity remains to transform health care to fully achieve reform. Although the future is uncertain, increased use of biosimilars in the US health care system could help achieve expanded access, control costs, and improve the quality of care.",
keywords = "Access, Affordable Care Act, Biologics, Health policy, Patient care",
author = "Ralph Boccia and Ira Jacobs and Robert Popovian and {de Lima Lopes}, Gilberto",
year = "2017",
month = "6",
day = "1",
doi = "10.2147/CMAR.S133442",
language = "English (US)",
volume = "9",
pages = "197--205",
journal = "Cancer Management and Research",
issn = "1179-1322",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Can biosimilars help achieve the goals of US health care reform?

AU - Boccia, Ralph

AU - Jacobs, Ira

AU - Popovian, Robert

AU - de Lima Lopes, Gilberto

PY - 2017/6/1

Y1 - 2017/6/1

N2 - The US Patient Protection and Affordable Care Act (ACA) aims to expand health care coverage, contain costs, and improve health care quality. Accessibility and affordability of innovative biopharmaceuticals are important to the success of the ACA. As it is substantially more difficult to manufacture them compared with small-molecule drugs, many of which have generic alternatives, biologics may increase drug costs. However, biologics offer demonstrated improvements in patient care that can reduce expensive interventions, thus lowering net health care costs. Biosimilars, which are highly similar to their reference biologics, cost less than the originators, potentially increasing access through reduced prescription drug costs while providing equivalent therapeutic results. This review evaluates 1) the progress made toward enacting health care reform since the passage of the ACA and 2) the role of biosimilars, including the potential impact of expanded biosimilar use on access, health care costs, patient management, and outcomes. Barriers to biosimilar adoption in the USA are noted, including low awareness and financial disincentives relating to reimbursement. The evaluated evidence suggests that the ACA has partly achieved some of its aims; however, the opportunity remains to transform health care to fully achieve reform. Although the future is uncertain, increased use of biosimilars in the US health care system could help achieve expanded access, control costs, and improve the quality of care.

AB - The US Patient Protection and Affordable Care Act (ACA) aims to expand health care coverage, contain costs, and improve health care quality. Accessibility and affordability of innovative biopharmaceuticals are important to the success of the ACA. As it is substantially more difficult to manufacture them compared with small-molecule drugs, many of which have generic alternatives, biologics may increase drug costs. However, biologics offer demonstrated improvements in patient care that can reduce expensive interventions, thus lowering net health care costs. Biosimilars, which are highly similar to their reference biologics, cost less than the originators, potentially increasing access through reduced prescription drug costs while providing equivalent therapeutic results. This review evaluates 1) the progress made toward enacting health care reform since the passage of the ACA and 2) the role of biosimilars, including the potential impact of expanded biosimilar use on access, health care costs, patient management, and outcomes. Barriers to biosimilar adoption in the USA are noted, including low awareness and financial disincentives relating to reimbursement. The evaluated evidence suggests that the ACA has partly achieved some of its aims; however, the opportunity remains to transform health care to fully achieve reform. Although the future is uncertain, increased use of biosimilars in the US health care system could help achieve expanded access, control costs, and improve the quality of care.

KW - Access

KW - Affordable Care Act

KW - Biologics

KW - Health policy

KW - Patient care

UR - http://www.scopus.com/inward/record.url?scp=85021370615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021370615&partnerID=8YFLogxK

U2 - 10.2147/CMAR.S133442

DO - 10.2147/CMAR.S133442

M3 - Review article

VL - 9

SP - 197

EP - 205

JO - Cancer Management and Research

T2 - Cancer Management and Research

JF - Cancer Management and Research

SN - 1179-1322

ER -